Key insights
- InvestingPro's fair value model flagged Tempus AI as overvalued in December 2025, preceding a 40% stock decline. The analysis highlighted the company's high valuation relative to its financials (revenue of $1.1B, EBITDA losses of $171M, and negative EPS of -$1.18). While the analysis proved accurate, the overall impact on the US market is limited to the specific stock.
When Tempus AI (NASDAQ:TEM) was trading at $76.66 in early December 2025, InvestingPro’s Fair Value models flagged a critical warning: the healthcare AI stock was significantly overvalued. Five months later, that analysis has proven remarkably prescient, with shares plummeting over 40% to $45.53 as of May 20, 2026. This case study demonstrates how Fair Value analysis helps investors identify better entry and exit points by calculating a stock’s intrinsic value through multiple valuation methodologies, enabling more informed investment decisions. For investors seeking current opportunities, the most overvalued list provides real-time analysis of stocks trading above their intrinsic value.
Tempus AI operates in the precision medicine space, leveraging artificial intelligence to analyze clinical and molecular data for cancer care and other diseases. In December 2025, when InvestingPro’s models identified the overvaluation, the company reported revenue of $1.1 billion but was burning cash with EBITDA losses of $171 million and negative EPS of -$1.18. The stock had experienced significant volatility in the preceding months, surging 34% in August before declining sharply through November and December. InvestingPro’s Fair Value calculation of $47.08 suggested the stock was overvalued by approximately 39%, signaling substantial downside risk despite the company’s growth trajectory. The company’s financial health score of 2.13 out of 5 provided additional context about its fundamental challenges.
InvestingPro’s analysis proved accurate as Tempus AI shares declined from $76.66 to $45.53, nearly reaching the Fair Value target and validating the overvaluation warning. Investors who heeded this signal could have avoided significant losses or identified optimal exit points. The stock’s descent occurred despite several positive catalysts, including Cathie Wood’s ARK funds repeatedly purchasing shares, a collaboration deal with Gilead, and the company achieving a record $1.1 billion in contract value. This disconnect between news flow and price action underscores the importance of valuation-based analysis.
Recent financial results have reinforced InvestingPro’s initial thesis. While revenue grew 23% to $1.36 billion, losses actually widened, with EBITDA deteriorating to -$185 million and EPS falling to -$1.72. The company’s Q1 2026 earnings showed a revenue beat but missed on earnings per share, with guidance failing to excite investors. H.C. Wainwright recently cut its price target to $64, though still above current levels. The stock recently touched a 52-week low of $41.73, reflecting ongoing valuation pressure.
InvestingPro’s Fair Value methodology aggregates multiple valuation approaches, including discounted cash flow models, comparable company analyses, and analyst consensus targets, to determine a stock’s intrinsic worth. This comprehensive framework is particularly valuable for high-growth companies with negative earnings, where traditional metrics may not capture the full picture. By calculating a margin of safety and analyzing future cash flow potential, Fair Value provides investors with a data-driven reference point for decision-making.
This successful analysis represents just one example of how InvestingPro’s tools help investors navigate complex markets. Beyond Fair Value, subscribers gain access to over 1,400 ProTips, comprehensive financial health scores, and AI-powered ProPicks portfolios with a proven track record. Learn more about InvestingPro to access Fair Value analysis for thousands of stocks and discover the next mispriced opportunity before the market catches on.